1. Home
  2. WFF vs AKTX Comparison

WFF vs AKTX Comparison

Compare WFF & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WF Holding Limited Ordinary Shares

WFF

WF Holding Limited Ordinary Shares

HOLD

Current Price

$0.43

Market Cap

11.1M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.28

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WFF
AKTX
Founded
1984
N/A
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
14.4M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
WFF
AKTX
Price
$0.43
$0.28
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
202.8K
1.9M
Earning Date
12-31-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,021,079.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.45
N/A
52 Week Low
$0.41
$0.22
52 Week High
$29.26
$1.73

Technical Indicators

Market Signals
Indicator
WFF
AKTX
Relative Strength Index (RSI) 44.91 37.34
Support Level $0.43 $0.27
Resistance Level $0.51 $0.31
Average True Range (ATR) 0.08 0.03
MACD -0.00 0.01
Stochastic Oscillator 10.07 66.67

Price Performance

Historical Comparison
WFF
AKTX

About WFF WF Holding Limited Ordinary Shares

WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: